Morning. My name is Alex Kim, and I'm the Chief Financial Officer of Standard BioTools Inc. It's a pleasure to welcome you to our 2026 Annual Meeting of Stockholders. I will act as chair of the meeting today and will record the minutes of this meeting. We're excited to be hosting our virtual meeting, which allows us to be more inclusive and reach a greater number of our stockholders. We have stockholders attending via the web portal and the 800 number that we have provided. We will conduct the business portion of our meeting first, and we will have an opportunity after the business portion of the meeting to review questions submitted in the designated field on the web portal, and we will address questions, if any, and as appropriate, at the end of the meeting.
In keeping with the digital approach to this year's meeting, it is now 11:31 A.M. Eastern Time and 8:31 A.M. Pacific Time on June 17th, 2026, and this meeting is officially called to order. I'd like to recognize the members of our board who are with us today, Thomas Carey, Chairman of the Board, Troy Cox, Fenel Eloi, Kathy Hibbs, and Frank Witney. I'd also like to introduce Sean Mackay, our Chief Business Officer, who is in attendance today. Finally, I would like to welcome Crystal Polly, our Inspector of Election for the meeting from American Election Services, John Rudy, our legal counsel from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., and Hitim Palmer from our auditors, PricewaterhouseCoopers LLP. This annual meeting is being held in accordance with the company's bylaws and Delaware law.
We'll begin today with the formal business of the meeting, which is to address the matters described in the company's proxy statement filed with the Securities and Exchange Commission on April 27th, 2026. When the balloting is complete, we'll announce the results of the vote and then adjourn the formal meeting. After the formal meeting has ended, we will have an opportunity to review questions submitted in the designated field on the web portal, and we will address questions, if any and as appropriate, at the end of the meeting. Only validated stockholders may ask questions in the designated field on the web portal. Out of consideration for others, please limit yourself to one question and restrict your questions to the procedures for the meeting and the proposals under consideration. Please note that this meeting is being recorded.
However, no one attending via the webcast or telephone is permitted to use any audio recording device. We will now proceed with the meeting. As noted in the proxy statement, the record date for voting at this meeting was April 24th, 2026. A list of stockholders as of the record date is available for your review. We have proof by affidavit that notice of this meeting has been duly given and that the proxy materials were mailed on or about April 27th, 2026, to all stockholders of record as of the close of business on April 24th, 2026, the record date for this annual meeting. A copy of the affidavit will be filed with the minutes of this meeting. The Inspector of Election has signed the inspector's oath, which will be filed with the minutes of this meeting.
The Inspector of Election has advised us that we have present by proxy a sufficient number of shares to constitute a quorum, so the meeting is duly convened for the purpose of transacting the business properly before it. For purposes of this annual meeting, we will vote by proxy and via the web portal today. For all matters to be voted upon at this annual meeting, each holder of common stock is entitled to one vote for each share of common stock held of record at the close of business on the record date. It is now 11:35 A.M. Eastern Time on June 17th, 2026, and the polls for each matter to be voted on at this meeting are now open.
The first order of business is the election of three Class I directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are duly elected and qualified. This item is discussed beginning on page 59 of the proxy statement. The board of directors has nominated Michael Egholm, PhD, Thomas Carey, and Eli Casdin to continue to serve as our Class I directors and recommends a vote for each nominee. The next order of business is the advisory vote on executive compensation as required by the Dodd-Frank Act, commonly known as the Say-on-Pay proposal. This item is discussed on page 60 of the proxy statement. Our board of directors recommends a vote for the approval of the compensation of our named executive officers for the year ended December 31, 2025.
The next order of business is the ratification of the appointment of the firm of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. This item is discussed beginning on page 62 of the proxy statement. Our board of directors recommends a vote for this proposal. The next order of business is the approval of the 2026 equity incentive plan. This item is discussed beginning on page 64 of the proxy statement. Our board of directors recommends a vote for the approval of the 2026 equity incentive plan. The next order of business is the approval of an amendment to our amended and restated 2017 employee stock purchase plan to increase the shares of common stock reserved for issuance thereunder by 1.2 million shares.
This item is discussed beginning on page 73 of the proxy statement. Our board of directors recommends a vote for the approval of the amendment to our amended and restated 2017 employee stock purchase plan. It is now 11:38 A.M. Eastern Time on June 17th, 2026, and the polls at this annual meeting are now closed. No additional ballots, proxies, votes, changes, or revocations will be accepted. The Inspector of Election has informed me that based upon the proxies we have received, with respect to proposal number one, Michael Egholm, PhD, Thomas Carey, and Eli Casdin have been elected as Class I directors of Standard BioTools. With respect to proposal number two, the compensation awarded to the company's named executive officers for the year ended December 31st, 2025 has been approved.
With respect to proposal number three, the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the 2026 fiscal year has been ratified. With respect to proposal number four, approval of the 2026 equity incentive plan has been approved. With respect to proposal number five, approval of the amendment to our amended and restated 2017 employee stock purchase plan has been approved. The final voting results will be set forth in a report of the Inspector of Election and will be included with the minutes of this meeting. We will also report the final voting results on a current report on Form 8-K, which we will file with the Securities and Exchange Commission. There being no further business to come before this meeting, the meeting is adjourned. Thank you for your attendance. We will now proceed with a question-and-answer session.
I would like to note that during the course of the question-and-answer session, we may make forward-looking statements regarding future events or the future financial performance of the company, which involves risks and uncertainties. Such statements are only predictions, and actual events or results could differ materially from those predictions due to a number of risks and uncertainties. I refer you to the documents the company files from time to time with the Securities and Exchange Commission, specifically the company's last filed Form 10-K for the year ended December 31, 2025, Form 10-Q for the quarter ended March 31, 2026, and the current reports on Form 8-K. These documents contain and identify important factors that could cause actual results to differ materially from those contained in our projections or forward-looking statements. These forward-looking statements speak only as of the dates thereof.
We disclaim any obligation to update these forward-looking statements, except as may be required by law. We have now come to the part of the agenda providing for general questions and discussion. We will take stockholders' questions as appropriate that have been entered today on the annual meeting web portal. As a courtesy to others, we will restrict questions to no more than one per stockholder. Sean, are there any questions?
There are no questions.
Thank you. The Q&A portion of the meeting is now closed. I want to thank you all for attending today's meeting and for your interest in Standard BioTools. We very much appreciate your attendance, and as always, thank you for your support.
This concludes today's meeting. Thank you for joining. You may now disconnect.